2024-12-13 - Analysis Report
## Exxon Mobil Corp (XOM) Stock Review

**1. Performance Comparison & Divergence:**

Exxon Mobil Corp (XOM), a leading international oil and gas company, has a cumulative return of 86.93% compared to the S&P 500 (VOO) with a cumulative return of 122.07%.  The difference is -35.1%, placing it at the 43.4th percentile of its historical performance relative to the S&P 500 based on the provided data.  This indicates XOM has underperformed the S&P 500 over the measured period.

**Alpha and Beta Analysis:**  The provided data shows variable performance relative to the market (Beta ~0.1), with periods of both outperformance and significant underperformance.  The alpha is consistently low, suggesting limited outperformance relative to the market risk taken.

**2. Recent Price Movement:**

* **Closing Price:** $111.92 (Last Market: $111.6)
* **5-Day Moving Average:** $113.17
* **20-Day Moving Average:** $117.63
* **60-Day Moving Average:** $118.19

The price is currently below all three moving averages, suggesting a potential downward trend.  The closing price is very close to the last market price, indicating minimal price movement on the last day.

**3. Technical Indicators & Expected Return:**

* **RSI (18.23):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.68):** Shows a bearish signal, confirming the downward trend indicated by the moving averages.
* **Relative Strength Change (20-day):** A decrease of -2.7% points to a short-term downward trend.
* **Expected Return (2+ years):** 0.0%.  This suggests that, based on the provided data, long-term investment in XOM may not significantly outperform the S&P 500.  This needs more comprehensive analysis for validation.


**4. Recent Earnings Analysis:**

The provided earnings data reveals some volatility:

* **EPS Trends:** EPS has fluctuated over the past few quarters, with a peak in Q1 2024 and a subsequent decline.
* **Beats and Misses:**  The company exceeded EPS expectations in Q1 and Q2 2024 and missed expectations in Q3 and Q4 2023. Q3 and Q4 2024 data are not provided.
* **Quarterly Comparison:** Earnings are generally strong but show some variance compared to the prior periods, not revealing a clear upward or downward trend.  More complete data is needed for reliable conclusions.


**5. Financial Information Analysis:**

* **Revenue:** Revenue is relatively stable, fluctuating around $80-90 Billion.  There's no clear upward or downward trend evident from this limited data.
* **Profit Margin:** Profit margins show some volatility, ranging from 21.67% to 25.27%.
* **Equity & ROE:** Equity and Return on Equity show significant fluctuations possibly due to various factors, such as stock buybacks or accounting adjustments.

**6. News and Recent Issues:**

No specific news or recent market outlook information is provided.  This section requires additional information.  Analyst opinions are not available.

**7. Overall Analysis:**

XOM has shown inconsistent performance compared to the S&P 500, significantly underperforming in the given period.  Technical indicators suggest an oversold condition, but the downward price trend and negative PPO signal caution. Earnings have been volatile, with occasional beats and misses of expectations, and lack a consistent upward trend. The provided financial data show fluctuating revenue, profit margins, and equity, with no clear, consistent upward trend.  Additional information regarding recent news, market outlook, and analyst opinions are needed for a more comprehensive analysis.  The 0.0% expected return relative to the S&P 500 over the long term based on the current data is noteworthy and indicates caution.  Further detailed investigation is crucial before making investment decisions.

**8. Disclaimer:** This analysis is based solely on the limited data provided.  It does not constitute financial advice.  Thorough independent research and consultation with a financial advisor are recommended before making any investment decisions.
